BRCA1 Protein

"BRCA1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). It contains an N-terminal RING FINGER DOMAIN and is a PROTEIN PHOSPHATASE 1 regulatory subunit. In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)

Descriptor ID	D019313
MeSH Number(s)	D12.776.313.125 D12.776.624.776.100 D12.776.660.100 D12.776.744.100 D12.776.930.137
Concept/Terms	BRCA1 Protein BRCA1 Protein Breast Cancer Type 1 Susceptibility Protein Breast Cancer 1 Protein Ring Finger Protein 53 BRCA1 Gene Product Breast Cancer 1 Gene Product

Below are MeSH descriptors whose meaning is more general than "BRCA1 Protein".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Fanconi Anemia Complementation Group Proteins [D12.776.313]
BRCA1 Protein [D12.776.313.125]
Neoplasm Proteins [D12.776.624]
Tumor Suppressor Proteins [D12.776.624.776]
BRCA1 Protein [D12.776.624.776.100]
Nuclear Proteins [D12.776.660]
BRCA1 Protein [D12.776.660.100]
Phosphoproteins [D12.776.744]
BRCA1 Protein [D12.776.744.100]
Transcription Factors [D12.776.930]
BRCA1 Protein [D12.776.930.137]

Below are MeSH descriptors whose meaning is related to "BRCA1 Protein".

Below are MeSH descriptors whose meaning is more specific than "BRCA1 Protein".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "BRCA1 Protein" by people in this website by year, and whether "BRCA1 Protein" was a major or minor topic of these publications.

Bar chart showing 42 publications over 24 distinct years, with a maximum of 5 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	2	2
1996	1	0	1
1998	1	0	1
1999	1	0	1
2001	1	0	1
2002	2	1	3
2003	0	1	1
2004	2	0	2
2006	4	0	4
2007	1	0	1
2008	1	0	1
2010	2	0	2
2011	1	0	1
2012	1	1	2
2013	0	1	1
2014	1	0	1
2016	1	1	2
2017	0	1	1
2019	2	1	3
2020	1	1	2
2021	5	0	5
2022	1	1	2
2024	1	0	1
2025	1	0	1

Below are the most recent publications written about "BRCA1 Protein" by people in Profiles.

Whalen JM, Earley J, Wisniewski C, Mercurio AM, Cantor SB. Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability. Nat Cancer. 2025 Feb; 6(2):278-291.

View in: PubMed
MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 Dec; 144:103775.

View in: PubMed
Bhardwaj PV, Abdou YG. Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. Curr Oncol Rep. 2022 12; 24(12):1791-1800.

View in: PubMed
Cong K, Cantor SB. Exploiting replication gaps for cancer therapy. Mol Cell. 2022 07 07; 82(13):2363-2369.

View in: PubMed
Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, And?jar-S?nchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021 11 18; 81(22):4692-4708.e9.

View in: PubMed
Cantor SB. Revisiting the BRCA-pathway through the lens of replication gap suppression: "Gaps determine therapy response in BRCA mutant cancer". DNA Repair (Amst). 2021 Nov; 107:103209.

View in: PubMed
Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaft LE, Ren B, McNeish I, Swisher E, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021 07 20; 36(3):109412.

View in: PubMed
Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021 08 05; 81(15):3128-3144.e7.

View in: PubMed
Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. Int J Mol Sci. 2021 May 24; 22(11).

View in: PubMed
Haddad JM, Robison K, Beffa L, Laprise J, ScaliaWilbur J, Raker CA, Clark MA, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants. J Genet Couns. 2021 12; 30(6):1570-1581.

View in: PubMed

People

Explore

Similar Concepts

Top Journals